| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30014306 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30014330 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30010713 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30007991 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30010714 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30007992 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30015925 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30015924 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30012871 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
| TVIS30012872 | HIV | ENSG00000198900.7 | protein_coding | TOP1 | Yes | No | 7150 | P11387 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TOP1 |
|---|---|
| DrugBank ID | DB01030 |
| Drug Name | Topotecan |
| Target ID | BE0000971 |
| UniProt ID | P11387 |
| Regulation Type | inhibitor |
| PubMed IDs | 11166732; 11443926; 12437383; 12520736; 12855624; 11752352; 9885371; 8853931; 9122737 |
| Citations | Schmidt F, Rieger J, Wischhusen J, Naumann U, Weller M: Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Eur J Pharmacol. 2001 Jan 19;412(1):21-5.@@strel'tsov SA, Mikheikin AL, Nechipurenko IuD: [Interaction of topotecan--a DNA topoisomerase I inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan]. Mol Biol (Mosk). 2001 May-Jun;35(3):442-50.@@Streltsov SA: Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I. J Biomol Struct Dyn. 2002 Dec;20(3):447-54.@@Zhang J, Pu SP, Zhou YJ: [Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan]. Ai Zheng. 2002 Dec;21(12):1305-9.@@Aisner J, Musanti R, Beers S, Smith S, Locsin S, Rubin EH: Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Clin Cancer Res. 2003 Jul;9(7):2504-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C: Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12.@@Herben VM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996 Aug;31(2):85-102.@@Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ: An overview of the clinical pharmacology of topotecan. Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18. |
| Groups | Approved; Investigational |
| Direct Classification | Camptothecins |
| SMILES | CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O |
| Pathways | |
| PharmGKB | PA451729 |
| ChEMBL | CHEMBL84 |
